Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 1, 2014, Pages 109-117

  Schell, Ryan F ^a   Sidone, Brian J ^a,g   Caron, Whitney P ^a   Walsh, Mark D ^a   White, Taylor F ^a   Zamboni, Beth A ^b   Ramanathan, Ramesh K ^c   Zamboni, William C ^a,d,e,f  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b CARLOW UNIVERSITY   (United States)

^c TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^d University of North Carolina at Chapel Hill   (United States)

^e Carolina Center of Cancer Nanotechnology Excellence   (United States)

^f North Carolina Biomedical Innovation Network   (United States)

^g DUQUESNE UNIVERSITY   (United States)

Author keywords

CKD 602; Liposomes; Pharmacokinetic; S CKD602; Sampling schema; Variability

Indexed keywords

ANTI-CANCER AGENTS; CKD-602; COEFFICIENT OF VARIANCE; LINEAR RELATIONSHIPS; LIPOSOMAL FORMULATION; PLASMA CONCENTRATION; S-CKD602; VARIABILITY;

LIPOSOMES; MOLECULES;

PHARMACOKINETICS;

ANTINEOPLASTIC AGENT; BELOTECAN; CISPLATIN; DOXORUBICIN; GLYCEROPHOSPHOETHANOLAMINE; IRINOTECAN; LURTOTECAN; OXALIPLATIN; PACLITAXEL; TIN; VINCRISTINE;

AREA UNDER THE CURVE; ARTICLE; DRUG CLEARANCE; DRUG FORMULATION; HUMAN; LIPOSOMAL DELIVERY; META ANALYSIS; PLASMA CONCENTRATION-TIME CURVE;

CKD-602; LIPOSOMES; PHARMACOKINETIC; S-CKD602; SAMPLING SCHEMA; VARIABILITY;

ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CAMPTOTHECIN; HUMANS; LIPOSOMES; NEOPLASMS;

EID: 84890977613     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.07.005     Document Type: Article

References (50)

1. Undevia S.D., Gomez-Abuin G., Ratain M.J. Pharmacokinetic variability of anticancer agents. Nat Rev Cancer 2005, 5(6):447-458.
2. Freyer G., et al. Pharmacokinetic studies in cancer chemotherapy: usefulness in clinical practice. Cancer Treat Rev 1997, 23(3):153-169.
3. Masson E., Zamboni W.C. Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes. Clin Pharmacokinet 1997, 32(4):324-343.
4. Wilkinson G.R. Drug metabolism and variability among patients in drug response. N Engl J Med 2005, 352(21):2211-2221.
5. Rudek M.A., et al. Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. Eur J Cancer 2004, 40(8):1170-1178.
6. Elis A., et al. Doxorubicin in lymphoma: association between pharmacokinetic variability and clinical response. Ther Drug Monit 2010, 32(1):50-52.
7. Joerger M., et al. Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors. Clin Cancer Res 2006, 12(7 Pt 1):2150-2157.
8. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005, 4(2):145-160.
9. Samad A., Sultana Y., Aqil M. Liposomal drug delivery systems: an update review. Curr Drug Deliv 2007, 4(4):297-305.
10. Yuan F., et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995, 55(17):3752-3756.
11. Ewert K.K., et al. Non-viral gene delivery with cationic liposome-DNA complexes. Methods Mol Biol 2008, 433:159-175.
12. Wang J., Sui M., Fan W. Nanoparticles for tumor targeted therapies and their pharmacokinetics. Curr Drug Metab 2010, 11(2):129-141.
13. Laginha K., Mumbengegwi D., Allen T. Liposomes targeted via two different antibodies: assay, B-cell binding and cytotoxicity. Biochim Biophys Acta 2005, 1711(1):25-32.
14. Zamboni W.C. Liposomal, nanoparticle, and conjugated formulations of anticancer agents. Clin Cancer Res 2005, 11(23):8230-8234.
15. Zamboni W.C., et al. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol 2004, 53(4):329-336.
16. Igarashi E. Factors affecting toxicity and efficacy of polymeric nanomedicines. Toxicol Appl Pharmacol 2008, 229(1):121-134.
17. Drummond D.C., et al. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J Pharm Sci 2008, 97(11):4696-4740.
18. Dos Santos N., et al. Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes. Biochim Biophys Acta 2002, 1561(2):188-201.
19. Woodle M.C., Lasic D.D. Sterically stabilized liposomes. Biochim Biophys Acta 1992, 1113(2):171-199.
20. Alexis F., et al. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008, 5(4):505-515.
21. Zamboni W.C., et al. Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies. Clin Pharmacol Ther 2009, 86(5):519-526.
22. Hempel G., et al. Population pharmacokinetics of liposomal daunorubicin in children. Br J Clin Pharmacol 2003, 56(4):370-377.
23. Hong Y., et al. Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases. Antimicrob Agents Chemother 2006, 50(3):935-942.
24. Gabizon A., et al. An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin. Cancer Chemother Pharmacol 2008, 61(4):695-702.
25. Hume D.A. The mononuclear phagocyte system. Curr Opin Immunol 2006, 18(1):49-53.
26. Drummond D.C., et al. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999, 51(4):691-743.
27. Papahadjopoulos D., et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 1991, 88(24):11460-11464.
28. Zamboni W.C., et al. Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies. Clin Cancer Res 2009, 15(4):1466-1472.
29. Meerum Terwogt J.M., et al. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin. Cancer Chemother Pharmacol 2002, 49(3):201-210.
30. White S.C., et al. Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br J Cancer 2006, 95(7):822-828.
31. Northfelt D.W., et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 1996, 36(1):55-63.
32. Hong R.L., Tseng Y.L. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity. Cancer 2001, 91(9):1826-1833.
33. Lyass O., et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000, 89(5):1037-1047.
34. Gabizon A., et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994, 54(4):987-992.
35. Gabizon A., et al. Development of liposomal anthracyclines: from basics to clinical applications. J Control Release 1998, 53(1-3):275-279.
36. Hubert A., et al. Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer. Anticancer Drugs 2000, 11(2):123-127.
37. Jones S.F., et al. Phase I and pharmacokinetic (PK) study of IHL-305 (pegylated liposomal irinotecan) in patients with advanced solid tumors. J Clin Oncol 2009, 27(15).
38. Duffaud F., et al. Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study. Eur J Cancer 2004, 40(18):2748-2752.
39. Veal G.J., et al. A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin. Br J Cancer 2001, 84(8):1029-1035.
40. Sankhala K.K., et al. A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin. J Clin Oncol 2009, 27(15).
41. Tan A.R., et al. Results of a clinical pharmacokinetic (PK) bioequiulence (BE) study of liposomal paclitaxel (LEP-ETU) versus paclitaxel (T) in patients with advanced cancer. J Clin Oncol 2006, 24(18):83s-s.
42. Embree L., et al. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. Cancer Chemother Pharmacol 1998, 41(5):347-352.
43. Bedikian A.Y., et al. Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients. J Clin Pharmacol 2006, 46(7):727-737.
44. Yang S.H., et al. A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor. Invest New Drugs 2010, 30:282-289.
45. Caron W.P., et al. Interpatient pharmacokinetic and pharmacodynamic variability of carrier-mediated anticancer agents. Clin Pharmacol Ther 2012, 91(5):802-812.
46. Song G., et al. Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs. J Liposome Res 2012, 22(3):177-192.
47. Koudelka S., Turánek J. Liposomal paclitaxel formulations. J Control Release 2012, 163(3):322-334.
48. Song G., et al. Relationship between complement factors and CC chemokines and the pharmacokinetics (PK) and pharmacodynamics (PD) of PEGylated liposomal doxorubicin (PLD) in patients with refractory epithelial ovarian cancer (EOC). 2012 Proceedings of 24th EORTC-NCI-AACR Symposium on 'Molecular Targets and Cancer Therapeutics, #126 2012.
49. Caron W., et al. Cellular function of the mononuclear phagocyte system as a phenotypic probe for pharmacokinetics (PK) and pharmacodynamics (PD) of PEGylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. Proceedings of ASCO 2012, #2591 2012.
50. La-Beck N.M., et al. Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. Cancer Chemotherapy Pharmacol 2012, 69:43-50.